Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.46 USD | -1.99% | +9.33% | -22.64% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.64% | 2.04Cr | |
+53.87% | 5.93TCr | |
+41.42% | 4.09TCr | |
-5.50% | 4.02TCr | |
-5.56% | 2.87TCr | |
+11.96% | 2.66TCr | |
-20.68% | 1.89TCr | |
+30.01% | 1.25TCr | |
+0.51% | 1.24TCr | |
+26.78% | 1.23TCr |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Transcript : Lumos Pharma, Inc., 2020 Earnings Call, Mar 09, 2021